[1]刘早阳 罗强 汪汉.贝伐单抗治疗非小细胞肺癌的高血压风险：一项系统评价[J].心血管病学进展,2021,(8):753-758.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.019]
　LIU Zaoyang,LUO Qiang,WANG Han.Hypertension Risk of Bevacizumab for Non-Small-Cell Lung Cancer:A Systematic Review[J].Advances in Cardiovascular Diseases,2021,(8):753-758.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.019]
点击复制

贝伐单抗治疗非小细胞肺癌的高血压风险：一项系统评价()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2021年8期
页码:
753-758
栏目:
论著
出版日期:
2021-08-25

文章信息/Info

Title:
Hypertension Risk of Bevacizumab for Non-Small-Cell Lung Cancer:A Systematic Review
作者:
刘早阳1 罗强2 汪汉2
(1.西南交通大学附属医院 成都市第三人民医院心胸外科,四川 成都 6100312.西南交通大学附属医院 成都市第三人民医院心内科,四川 成都 610031)
Author(s):
LIU Zaoyang1; LUO Qiang2; WANG Han2
(1.Department of Cardiothoracic Surgery,The Third Peoples Hospital of Chengdu ,The Affiliated Hospital of Southwest Jiaotong University,Chengdu 610031,Sichuan,China 2.Department of Cardiology,The Third Peoples Hospital of Chengdu,The Affiliated Hospital of Southwest Jiaotong University,Chengdu 610031,Sichuan,China)
关键词:
贝伐单抗; 非小细胞肺癌; 高血压; 系统评价
Keywords:
Bevacizumab Non-small-cell lung cancerHypertensionSystematic review
DOI:
10.16806/j.cnki.issn.1004-3934.2021.08.019
摘要:
目的 贝伐单抗广泛用于治疗大肠癌、肺癌和乳腺癌，但部分研究发现使用贝伐单抗治疗非小细胞肺癌(NSCLC)患者高血压的发生风险明显增加。本荟萃分析旨在确定使用贝伐单抗治疗NSCLC患者高血压的总体风险。方法 从Embase、PubMed和Cochrane 等相关电子数据库进行相关检索，检索时间为建库开始至2021年8月1日，收集以贝伐单抗为干预措施治疗NSCLC的随机对照试验。采用随机效应或固定效应模型提取数据，计算总体发病率、比值比(OR)和95% CI 。结果 该研究共纳入13篇文章，共4 116例（试验组1 936例，对照组2 280例）。NSCLC患者中，接受贝伐单抗的患者全级别和3级以上高血压发生率分别为17%（95% CI 8% ～26%）和8%（95% CI 5% ～11%）。其次，接受贝伐单抗的患者高血压和3级以上高血压的风险增加[OR=2.05（95% CI 1.37～2.72），I2=0，P＜0.001；OR=1.41（95% CI 1.01～1.81），I2=0，P＜0.001]。结论 贝伐单抗治疗NSCLC患者发生高血压的风险显著增加。
Abstract:
Objective Bevacizumab is widely used in the treatment of colorectal cancer,lung cancer and breast cancer. However,some studies have found that the risk of hypertension in patients with non-small-cell lung cancer(NSCLC) is significantly increased by using bevacizumab. The purpose of this meta-analysis was to determine the overall risk of hypertension in patients with NSCLC treated with bevacizumab. Methods Randomized controlled trials of bevacizumab for NSCLC was collected from Embase,PubMed,Cochrane and other related electronic databases from the beginning of database construction to August 1,2021. The data were extracted and the total incidence,odds ratio( OR) and 95% CI were calculated using random effect or fixed effect model. Results A total of 13 articles were included in this study,including 4 116 cases(1 936 cases in the experimental group and 2 280 cases in the control group). In patients with NSCLC,the incidences of all-grade and above grade 3 hypertension in patients who received bevacizumab were 17%(95% CI 8%～26%) and 8%(95% CI 5%～11%) respectively. Patients who received bevacizumab had an increased risk of hyper tension and above grade 3 hyper tension[OR=2.05（95% CI 1.37～2.72），I2=0，P＜0.001；OR=1.41（95% CI 1.01～1.81）， I2=0，P＜0.001]. Conclusion Bevacizumab significantly increases the risk of hypertension in patients with NSCLC.

参考文献/References:

[1] Syrigos KN,Karapanagiotou E,Boura P,et al. Bevacizumab-induced hypertension:pathogenesis and management[J]. BioDrugs,2011,25(3):159-169.

[2] Plummer C,Michael A,Shaikh G,et al. Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK[J]. Br J Cancer,2019,121(2):109-116.

[3] Chen J,Lu Y,Zheng Y. Incidence and risk of hypertension with bevacizumab in non-small-cell lung cancer patients:a meta-analysis of randomized controlled trials[J]. Drug Des Devel Ther,2015,9:4751-4760.

[4] Johnson DH,Fehrenbacher L,Novotny WF,et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer[J]. J Clin Oncol,2004,22(11):2184-2191.

[5] Herbst RS,Ansari R,Bustin F,et al. Effcacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy(BeTa):a double-blind,placebo-controlled,phase 3 trial[J]. Lancet,2011,377(9780):1846-1854

[6] Niho S,Kunitoh H,Nokihara H,et al. Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer[J]. Lung Cancer,2012,76(3):362-367.

[7] Reck M,von Pawel J,Zatloukal P,et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil[J]. J Clin Oncol,2009,27(8):1227-1234.

[8] Sandler A,Gray R,Perry MC,et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer[J]. N Engl J Med,2006,355(24):2542-2550.

[9] Herbst RS,O’Neill VJ,Fehrenbacher L,et al. Phase II study of effcacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer[J]. J Clin Oncol,2007,25(30):4743-4750.

[10] Soria JC,Márk Z,Zatloukal P,et al. Randomized phase II study of dulanermin in combination with paclitaxel,carboplatin,and bevacizumab in advanced non-small-cell lung cancer[J]. J Clin Oncol,2011,29(33):4442-4451.

[11] Spigel DR,Greco FA,Waterhouse DM,et al. Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer [J]. Lung Cancer,2012,78(1):70-77.

[12] Boutsikou E,Kontakiotis T,Zarogoulidis P,et al. Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer[J]. Onco Targets Ther,2013,6:125-134.

[13] Zhou C,Wu YL,Chen G,et al. A randomized,double-blind,placebo-controlled,multicenter,phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer[J]. J Clin Oncol,2015,33(19):2197-204.

[14] Galetta D,Cinieri S,Pisconti S,et al. Cisplatin/pemetrexed followed by maintenance pemetrexed versus carboplatin/paclitaxel/bevacizumab followed by maintenance bevacizumab in advanced nonsquamous lung cancer:The GOIM(Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized Trial[J]. Clin Lung Cancer,2015,16(4):262-73.

[15] Ramalingam SS,Dahlberg SE,Belani CP,et al. Pemetrexed,bevacizumab,or the combination as maintenance therapy for advanced nonsquamous non-small-cell lung cancer:ECOG-ACRIN 5508[J]. J Clin Oncol,2019,37(26):2360-2367.

[16] Stinchcombe TE,J?nne PA,Wang X,et al. Effect of erlotinib plus bevacizumab vs erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non-small cell lung cancer:a phase 2 randomized clinical trial[J]. JAMA Oncol,2019,5(10):1448-1455.

相似文献/References:

[1]古力尼尕尔·麦麦提吐尔孙 付真彦.肺癌靶向治疗药物EGFR-TKI与其心脏毒性的研究进展[J].心血管病学进展,2022,(2):128.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.009]
　GULINIGAER·Maimaitituersun,FU Zhenyan.EGFR-TKI and Its Cardiotoxicity in Lung Cancer[J].Advances in Cardiovascular Diseases,2022,(8):128.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.009]

备注/Memo

备注/Memo:
基金项目：四川省科技厅面上项目（19YYJC0580）；四川省中医药管理局（2020JC0010） 通信作者：汪汉，E-mail:wanghan@wsjtu.edu.com 收稿日期：2021-08-07
更新日期/Last Update: 2021-09-26